Introduction
Hodgkin Lymphoma (HL) is one of the most commonly occurring malignancies
in adolescents and young adults, curable in the majority of cases.
Unfortunately, a subgroup of patients do not enter remission with front
line therapy or relapse after initial response to therapy (R/R cHL). In
such cases, treatment options are different regimens of chemotherapy,
radiotherapy, high-dose chemotherapy plus autologous stem cell
transplantation (HDCT/ASCT), and immunotherapy1,2.
Many regimens have been proposed1 and recently novel
agents are increasingly involved in order to achieve a better response
without increasing the toxicity burden. Brentuximab Vedotin (BV) is an
antibody-drug conjugate combining the anti-CD30 monoclonal antibody with
the monomethyl auristatin-E. Studies are evaluating the combination of
BV with classical regimens mainly in adults, while limited is the
experience in paediatrics.
Recently a phase II study3 investigated for the first
time BV plus the DHAP regimen as salvage therapy in adults, with
encouraging results. The experience with this regimen in children or
adolescent has not been described so far.